PROVIDENCE – Lifespan Corp is offering patients streamlined access to clinical trials through a new portal on its website.
The feature allows users to search hundreds of active and enrolling clinical trials by consolidating the information into one place, including tests on new drugs, devices and diagnostics for people with diseases such as cancer, heart disease, diabetes, or with neurological conditions such as brain injuries.
Building a Strong Data Foundation in the Age of AI
Artificial intelligence (AI) has become a key priority in the boardroom and across management —…
Learn More
“Hundreds of clinical research studies are currently underway, and this endeavor is a natural next step to connect our research community with the patients they seek to serve,” said Dr. Bharat Ramratnam, Lifespan’s chief science officer.
Searchable by disease, condition or procedure, the portal also collects information on healthy volunteer trials.
“We’re proud to share this new platform, intended to make our cutting-edge research more accessible to those who need it most,” said Dr. Timothy J. Babineau, Lifespan’s CEO and president. “We’re confident that it will make it easier for patients and providers to find the best trial options, and for our researchers to recruit study participants, harnessing the power of our impressive research enterprise on behalf of our community.”
The portal is accessible at Lifespan.org, on the site’s top navigation bar. The search engine gathers study information from ClinicalTrials.gov, a site maintained by the National Library of Medicine at the National Institutes of Health.
“Our goal is to offer patients, families and physicians access to that information in a way that is matched to their needs, with studies close to home, and in language that is clear and accessible to patients and families who are often faced with a whole new vocabulary of clinical terminology after a diagnosis,” said Peggy McGill, Lifespan’s vice president of research administration.
Lifespan says its external research funding topped $84 million in fiscal year 2018.
